TherapeuticsMD (TXMD) Receivables (2010 - 2025)

TherapeuticsMD (TXMD) has reported Receivables for 16 consecutive years, with $20.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 10.25% year-over-year to $20.8 million; the trailing twelve-month figure through Dec 2025 stood at $20.8 million (down 10.25% YoY), and the FY2025 full-year result was $20.8 million, down 10.25% from the prior year.
• Receivables declined to $20.8 million in Q4 2025 per TXMD's latest filing, from $23.1 million in the prior quarter.
• Across five years, Receivables topped out at $45.8 million in Q2 2022 and bottomed at $20.8 million in Q4 2025.
• Historically, Receivables has averaged $32.3 million across 5 years, with a median of $33.6 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Receivables soared 83.05% in 2021, then decreased 14.02% in 2022.
• Over 5 years, Receivables stood at $36.2 million in 2021, then retreated by 11.11% to $32.2 million in 2022, then slipped by 23.3% to $24.7 million in 2023, then slipped by 6.2% to $23.1 million in 2024, then slipped by 10.25% to $20.8 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $20.8 million, $23.1 million, and $24.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.